Generated with Avocode.Line 2Line 3

Clinical AI in Healthcare: Unlocking Value & Driving Innovation

Join us August 8 for a live webinar presented by Dr. Samir Kumar.
Technology Data Communication

The Gold Standard for Advanced Vascular and Neurovascular Imaging Worldwide

After initial validation in an NIH-sponsored DEFUSE 2 study, published in 2012, and extensively studied in 14 worldwide clinical trials, iSchemaView purchased the technology rights to the software that same year. Since then, adoption of the Rapid® platform has quickly grown.

a proven solution

Making an Impact

In early 2019, iSchemaView received FDA clearance that allows physicians to use our neuroimaging platform to select stroke patients likely to benefit from endovascular thrombectomy (clot removal). We believe this advancement will benefit smaller community hospitals and the patients they serve.


Our Experienced Team

Considered the preeminent brain imaging platform, we also have a highly experienced leadership team. Co-founders Dr. Greg Albers and Dr. Roland Bammer, along with software engineer Matus Straka are recognized leaders in cerebrovascular neuroscience, cerebrovascular radiology, and software engineering. Our mission is to continue to redefine and improve stroke care, providing healthcare organizations with the fastest, most advanced technology to facilitate the diagnosis and treatment of stroke.

View RapidAI Leadership
Greg Albers and Ronald Bammer
Time Every Brain

Become Part of the RapidAI Revolution

If you are interested in learning more about including RapidAI in a clinical study, Contact Us.

RapidAI Clinical Trials

Find out about the most influential stroke clinical trials taking place worldwide. The objective, status, design, endpoint.
See All Clinical Trials.

RapidAI Trial Results

From early to late-window results, RapidAI has achieved the best results ever obtained in endovascular stroke studies.
See All Trial Results.


The Most Comprehensive Stroke Platform


Rapid ICH

The latest in artificial intelligence for fast, automated detection of intracranial hemorrhage.



Automatically generates measurements to indicate early ischemic change on NCCT scans.


Rapid CTA & Rapid LVO

Fast Identification of Suspected LVOs and regions of asymmetry in blood vessel density.

Rapid CTP

Rapid CTP

Fast, automated assessment of patients who are likely to benefit from endovascular thrombectomy.

Rapid MRI

Rapid MRI

Automatically identifies brain areas with low ADC values and delayed contrast arrival.

Rapid Web App

Rapid Web App

Get notifications for new cases and access Rapid results using Google Chrome or Microsoft Edge on any desktop or laptop — saving you and your patients precious time.

RapidAI Mobile App

Rapid Mobile App

Anytime, anywhere access to RapidAI results plus the ability to communicate about patient care.

SUCCESS stories

Revolutionizing Neurovascular Imaging and Patient Care

RapidAI Software at The University of Kansas Hospital

A Conversation with Dr. Blaise Baxter

Revolutionary Stroke Scan Software

“Our research use of Rapid has shown that its speed and accuracy are very helpful in the management of patients with acute stroke. Rapid plays an important role in selecting which patients should be urgently transferred to regional stroke centers for endovascular therapy."

Frank Silver, MD
Professor of Neurology, University of Toronto; Medical Director, Toronto West Stroke Network; and Medical Director, Ontario Telestroke Program

“...We used Rapid in the EXTEND, EXTEND-IA and EXTEND-IA TNK randomized trials at over 20 sites across Australia and New Zealand. It's straightforward to install and works with the full range of CT and MR devices and PACS systems. The fully automated results are robust to common artefacts, easily interpretable and provide standardization across sites with a range of imaging experience.”

Bruce Campbell, MBBS(Hons), BMedSc, PhD, FRACP
Professional Fellow, Department of Medicine, University of Melbourne and Head of Stroke, Royal Melbourne Hospital

"Advanced imaging with Rapid was instrumental in changing the AHA guidelines for thrombectomy (mechanical reperfusion) and has the potential to be equally impactful for thrombolysis (chemical reperfusion)."

Marilyn Rymer, MD
Professor of Neurology, University of Kansas Medical Center and Vice President for Neuroscience, The University of Kansas Hospital
schedule a demo

Discover How You Can Use RapidAI

Talk with an Expert